TANOVEA® (rabacfosadine for injection) becomes the first-ever fully approved drug for the treatment of lymphoma in dogs and is acquired by Elanco Animal Health.

On July 15, 2021, TANOVEA® (rabacfosadine for injection) received full approval from FDA’s Center for Veterinary Medicine for the treatment of lymphoma in dogs, making this the only animal drug for dogs that has ever advanced from a conditional to full FDA approval under the FDA’s Minor Use and Minor Species (MUMS) program. Concurrently, Elanco Animal Health Incorporated (NYSE: ELAN) announced the acquisition of TANOVEA® from VetDC, the Fort Collins, Colorado company credited with developing and commercializing this product.